Skip to content

Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles

Research output: Contribution to journalArticle

  • John M Gregson
  • Daniel F Freitag
  • Praveen Surendran
  • Nathan O Stitziel
  • Rajiv Chowdhury
  • Stephen Burgess
  • Kaptoge Stephen
  • Pei Gao
  • James R Staley
  • Peter Willeit
  • Sune F Nielsen
  • Muriel Caslake
  • Stella Trompet
  • Linda M Polfus
  • Kari Kuulasmaa
  • Jukka Kontto
  • Markus Perola
  • Stefan Blankenberg
  • Giovanni Veronesi
  • Francesco Gianfagna
  • Satu Mannisto
  • Akinori Kimura
  • Honghuang Lin
  • Dermot F Reilly
  • Mathias Gorski
  • Vladan Mijatovic
  • CKDGen consortium
  • Patricia B Munroe
  • Georg B Ehret
  • International Consortium for Blood Pressure
  • Alex Thompson
  • Maria Uria-Nickelsen
  • Anders Malarstig
  • Abbas Dehghan
  • CHARGE inflammation working group
  • Thomas F Vogt
  • Taishi Sasaoka
  • Fumihiko Takeuchi
  • Norihiro Kato
  • Yoshiji Yamada
  • Frank Kee
  • Martina Muller-Nurasyid
  • Jean Ferrieres
  • Dominique Arveiler
  • Philippe Amouyel
  • Veikko Salomaa
  • Eric Boerwinkle
  • Simon G Thompson
  • Ian Ford
  • J Wouter Jukema
  • Naveed Sattar
  • Chris J Packard
  • Abdulla al Shafi Majumder
  • Dewan S Alam
  • Panos Deloukas
  • Heribert Schunkert
  • Nilesh J Samani
  • Sekar Kathiresan
  • MICAD Exome consortium
  • Borge G Nordestgaard
  • Danish Saleheen
  • Joanna M M Howson
  • Emanuele Di Angelantonio
  • Adam S Butterworth
  • John Danesh
  • EPIC-CVD consortium
  • CHD Exome+ consortium
Original languageEnglish
Pages (from-to)492-504
Number of pages13
JournalEuropean Journal of Preventive Cardiology
Issue number5
Early online date8 Dec 2016
DateAccepted/In press - 24 Oct 2016
DateE-pub ahead of print - 8 Dec 2016
DatePublished (current) - 3 Mar 2017


Aims Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), has not reduced risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA2 enzyme activity is causally relevant to coronary heart disease. Methods In 72,657 patients with coronary heart disease and 110,218 controls in 23 epidemiological studies, we genotyped five functional variants: four rare loss-of-function mutations (c.109+2T > C (rs142974898), Arg82His (rs144983904), Val279Phe (rs76863441), Gln287Ter (rs140020965)) and one common modest-impact variant (Val379Ala (rs1051931)) in PLA2G7, the gene encoding Lp-PLA2. We supplemented de-novo genotyping with information on a further 45,823 coronary heart disease patients and 88,680 controls in publicly available databases and other previous studies. We conducted a systematic review of randomized trials to compare effects of darapladib treatment on soluble Lp-PLA2 activity, conventional cardiovascular risk factors, and coronary heart disease risk with corresponding effects of Lp-PLA2-lowering alleles. Results Lp-PLA2 activity was decreased by 64% (p = 2.4 × 10–25) with carriage of any of the four loss-of-function variants, by 45% (p < 10–300) for every allele inherited at Val279Phe, and by 2.7% (p = 1.9 × 10–12) for every allele inherited at Val379Ala. Darapladib 160 mg once-daily reduced Lp-PLA2 activity by 65% (p < 10–300). Causal risk ratios for coronary heart disease per 65% lower Lp-PLA2 activity were: 0.95 (0.88–1.03) with Val279Phe; 0.92 (0.74–1.16) with carriage of any loss-of-function variant; 1.01 (0.68–1.51) with Val379Ala; and 0.95 (0.89–1.02) with darapladib treatment. Conclusions In a large-scale human genetic study, none of a series of Lp-PLA2-lowering alleles was related to coronary heart disease risk, suggesting that Lp-PLA2 is unlikely to be a causal risk factor.

Download statistics

No data available



  • Supplementary information PDF

    Accepted author manuscript, 871 KB, PDF document

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Sage at Please refer to any applicable terms of use of the publisher.

    Final published version, 285 KB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups